Cargando…
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
Evolocumab is a PCSK9 inhibitor which is administered subcutaneously, and when added to statin therapy it has been shown to cause a significant incremental LDL-C reduction, leading to a reduction of cardiovascular risk. Evolocumab has a favorable side effect profile, and its self-administration at h...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214408/ https://www.ncbi.nlm.nih.gov/pubmed/30464416 http://dx.doi.org/10.2147/PPA.S149423 |